Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
senrebotase
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Injection
01
Overview
Senrebotase is an engineered botulinum neurotoxin derivative developed for the treatment of overactive bladder and postherpetic neuralgia. It is a recombinant protein designed to target specific neuronal pathways involved in these conditions. The drug acts as an antagonist at nociceptin/orphanin FQ peptide (OOR) receptor and soluble NSF attachment protein receptor (SNARE) complex, thereby inhibiting neurotransmitter release and modulating pain or bladder function. Senrebotase completed phase 2 clinical trials for overactive bladder syndrome and postherpetic neuralgia but was discontinued before approval. The original developer was Health Protection Agency Porton Down1, with later development by Allergan UC (now part of AbbVie). Its modality is classified as a peptide/protein therapeutic administered by injection[1][2][3][5][7].
- Other names
- senrebotase
02
Targets
NOP (Nociceptin/orphanin FQ peptide receptor)VAMP (SNARE Protein Complex)
Beyond the preview
Go deeper on senrebotase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on senrebotase.